The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
Abstract
Purpose: To develop and validate a model that can be used to predict the overall survival probability among metastatic hormone-refractory prostate cancer patients (HRPC). Patients and Methods: Data from six Cancer and Leukemia Group B protocols that enrolled 1,101 patients with metastatic hormone-refractory adenocarcinoma of the prostate during the study period from 1991 to 2001 were pooled. The proportional hazards model was used to develop a multivariable model on the basis of pretreatment factors and to construct a prognostic model. The area under the receiver operating characteristic curve (ROC) was calculated as a measure of predictive discrimination. Calibration of the model predictions was assessed by comparing the predicted probability with the actual survival probability. An independent data set was used to validate the fitted model. Results: The final model included the following factors: lactate dehydrogenase, prostate-specific antigen, alkaline phosphatase, Gleason sum, Eastern Cooperative Oncology Group performance status, hemoglobin, and the presence of visceral disease. The area under the ROC curve was 0.68. Patients were classified into one of four risk groups. We observed a good agreement between the observed and predicted survival probabilities for the four risk groups. The observed median survival durations were 7.5 (95% confidence interval [CI], 6.2 to 10.9), 13.4 (95% CI, 9.7 to 26.3), 18.9 (95% CI, 16.2 to 26.3), and 27.2 (95% CI, 21.9 to 42.8) months for the first, second, third, and fourth risk groups, respectively. The corresponding median predicted survival times were 8.8, 13.4, 17.4, and 22.80 for the four risk groups. Conclusion: This model could be used to predict individual survival probabilities and to stratify metastatic HRPC patients in randomized phase III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Self-citationRegression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Self-citationRegression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A leisurely look at the bootstrap, the jackknife, and cross-validation
Efron, B., & Gong, G. (1983) · The American Statistician · doi:10.1080/00031305.1983.10483087 · Cited by 3,229
Regression modelling strategies for improved prognostic prediction
Harrell, F. E., Lee, K. L., Califf, R. M., Pryor, D. B., & Rosati, R. A. (1984) · Statistics in Medicine · doi:10.1002/sim.4780030207 · Cited by 1,798
Partin, A. W. (1997) · JAMA · doi:10.1001/jama.277.18.1445 · Cited by 1,794
Partin, A. W., Yoo, J., Carter, H. B., Pearson, J. D., Chan, D. W., Epstein, J. I., & Walsh, P. C. (1993) · Journal of Urology · doi:10.1016/s0022-5347(17)35410-1 · Cited by 1,278
Kantoff, P. W., Halabi, S., Conaway, M., Picus, J., Kirshner, J., Hars, V., Trump, D., Winer, E. P., & Vogelzang, N. J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2506 · Cited by 890
Self-citationD'Amico, A. V., Whittington, R., Malkowicz, S. B., Fondurulia, J., Chen, M.-H., Kaplan, I., Beard, C. J., Tomaszewski, J. E., Renshaw, A. A., Wein, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.1.168 · Cited by 389
Cited by
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Self-citationAbiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Self-citationScher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Self-citationScher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,654
Self-citationSmall, E. J., Schellhammer, P. F., Higano, C. S., Redfern, C. H., Nemunaitis, J. J., Valone, F. H., Verjee, S. S., Jones, L. A., & Hershberg, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5252 · Cited by 1,108
Self-citationKantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Self-citationPROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
Cheever, M. A., & Higano, C. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3126 · Cited by 780
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H., Schwartz, L., Larson, S., Fleisher, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1506 · Cited by 665
Scher, H. I., Jia, X., de Bono, J. S., Fleisher, M., Pienta, K. J., Raghavan, D., & Heller, G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70340-1 · Cited by 611
Small, E. J., Halabi, S., Dawson, N. A., Stadler, W. M., Rini, B. I., Picus, J., Gable, P., Torti, F. M., Kaplan, E., & Vogelzang, N. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.037 · Cited by 504
Self-citationKelly, W. K., Halabi, S., Carducci, M., George, D., Mahoney, J. F., Stadler, W. M., Morris, M., Kantoff, P., Monk, J. P., Kaplan, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4767 · Cited by 483
Self-citationHalabi, S., Lin, C.-Y., Kelly, W. K., Fizazi, K. S., Moul, J. W., Kaplan, E. B., Morris, M. J., & Small, E. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3696 · Cited by 478
Self-citationHalabi, S., Kelly, W. K., Ma, H., Zhou, H., Solomon, N. C., Fizazi, K., Tangen, C. M., Rosenthal, M., Petrylak, D. P., Hussain, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.7270 · Cited by 461
Self-citationTagawa, S. T., Milowsky, M. I., Morris, M., Vallabhajosula, S., Christos, P., Akhtar, N. H., Osborne, J., Goldsmith, S. J., Larson, S., Taskar, N. P., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0231 · Cited by 427
James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., De Bono, J. S., Gale, J., Hetherington, J., Hoskin, P. J., Jones, R. J., Laing, R., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.032 · Cited by 425
Scher, H. I., Heller, G., Molina, A., Attard, G., Danila, D. C., Jia, X., Peng, W., Sandhu, S. K., Olmos, D., Riisnaes, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.3487 · Cited by 379
Armstrong, A. J., Halabi, S., Luo, J., Nanus, D. M., Giannakakou, P., Szmulewitz, R. Z., Danila, D. C., Healy, P., Anand, M., Rothwell, C. J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01731 · Cited by 362
Self-citationArmstrong, A. J., Garrett-Mayer, E. S., Yang, Y.-C. O., de Wit, R., Tannock, I. F., & Eisenberger, M. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1036 · Cited by 359
Prostate cancer as a model for tumour immunotherapy
Drake, C. G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2817 · Cited by 347
Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate Cancer
Gandaglia, G., Karakiewicz, P. I., Briganti, A., Passoni, N. M., Schiffmann, J., Trudeau, V., Graefen, M., Montorsi, F., & Sun, M. (2015) · European Urology · doi:10.1016/j.eururo.2014.07.020 · Cited by 334
Gulley, J. L., Arlen, P. M., Madan, R. A., Tsang, K.-Y., Pazdur, M. P., Skarupa, L., Jones, J. L., Poole, D. J., Higgins, J. P., Hodge, J. W., et al. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-009-0782-8 · Cited by 297
Self-citationCarducci, M. A., Saad, F., Abrahamsson, P., Dearnaley, D. P., Schulman, C. C., North, S. A., Sleep, D. J., Isaacson, J. D., Nelson, J. B., & for the Atrasentan Phase III Study Group Institutions. (2007) · Cancer · doi:10.1002/cncr.22996 · Cited by 294
Gulley, J. L., Borre, M., Vogelzang, N. J., Ng, S., Agarwal, N., Parker, C. C., Pook, D. W., Rathenborg, P., Flaig, T. W., Carles, J., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.02031 · Cited by 285
Self-citationTherapeutic Cancer Vaccines: Current Status and Moving Forward
Schlom, J. (2012) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djs033 · Cited by 282
Lactate Dehydrogenases as Metabolic Links between Tumor and Stroma in the Tumor Microenvironment
Mishra, D., & Banerjee, D. (2019) · Cancers · doi:10.3390/cancers11060750 · Cited by 277
Armstrong, A. J., Garrett-Mayer, E., Ou Yang, Y.-C., Carducci, M. A., Tannock, I., de Wit, R., & Eisenberger, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4769 · Cited by 275
Rathkopf, D. E., Smith, M. R., de Bono, J. S., Logothetis, C. J., Shore, N. D., de Souza, P., Fizazi, K., Mulders, P. F. A., Mainwaring, P., Hainsworth, J. D., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.056 · Cited by 274
Self-citationTherapeutic cancer vaccines: Are we there yet?
Klebanoff, C. A., Acquavella, N., Yu, Z., & Restifo, N. P. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00979.x · Cited by 271
An updated catalog of prostate cancer predictive tools
Shariat, S. F., Karakiewicz, P. I., Roehrborn, C. G., & Kattan, M. W. (2008) · Cancer · doi:10.1002/cncr.23908 · Cited by 264
Self-citationSheikh, N. A., Petrylak, D., Kantoff, P. W., dela Rosa, C., Stewart, F. P., Kuan, L.-Y., Whitmore, J. B., Trager, J. B., Poehlein, C. H., Frohlich, M. W., et al. (2013) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1317-2 · Cited by 263
Self-citationChi, K. N., Kheoh, T., Ryan, C. J., Molina, A., Bellmunt, J., Vogelzang, N. J., Rathkopf, D. E., Fizazi, K., Kantoff, P. W., Li, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv594 · Cited by 167
Self-citationSecondary Hormonal Therapy for Advanced Prostate Cancer
Lam, J. S., Leppert, J. T., Vemulapalli, S. N., Shvarts, O., & Belldegrun, A. S. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00034-0 · Cited by 153
Fizazi, K., Massard, C., Smith, M., Rader, M., Brown, J., Milecki, P., Shore, N., Oudard, S., Karsh, L., Carducci, M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.10.001 · Cited by 142
Armstrong, A. J., Lin, P., Higano, C. S., Sternberg, C. N., Sonpavde, G., Tombal, B., Templeton, A. J., Fizazi, K., Phung, D., Wong, E. K., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy406 · Cited by 71
Halabi, S., Yang, Q., Roy, A., Luo, B., Araujo, J. C., Logothetis, C., Sternberg, C. N., Armstrong, A. J., Carducci, M. A., Chi, K. N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02661 · Cited by 30
Self-citationMurtojärvi, M., Halkola, A. S., Airola, A., Laajala, T. D., Mirtti, T., Aittokallio, T., & Pahikkala, T. (2020) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2019.104014 · Cited by 14
Metadata
- Authors
- Halabi, S., Small, E. J., Kantoff, P. W., Kattan, M. W., Kaplan, E. B., Dawson, N. A., Levine, E. G., Blumenstein, B. A., & Vogelzang, N. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-04-01
- Volume
- 21
- Issue
- 7
- Pages
- 1232-1237
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2103090668
- Cited by
- 674
- References
- 25
- FWCI
- 18.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.